APOA1 antibody

Catalog No. ABIN116540

Product Details anti-APOA1 Antibody

Target: APOA1 (Apolipoprotein A-I (APOA1))

Reactivity: Human

Host: Goat

Clonality: Polyclonal

Conjugate: This APOA1 antibody is un-conjugated

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro))

Specificity: Typically less than 1 % cross reactivity against other types of Apolipoprotein was detected by ELISA against purified standards. This antibody reacts with Human Apolipoprotein A-I and has negligible cross-reactivity with Type A-II, B, C-I, C-II, C-III, E and J Apolipoproteins. Non-specific cross reaction of anti-Apolipoprotein antibodies with other Human serum proteins is negligible.

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Immunoaffinity Chromatography using immobilized antigens followed by extensive cross-adsorption against other Apolipoproteins and human serum proteins to remove any unwanted specificities.

Immunogen: Apolipoprotein Type A-I was isolated from Human plasma by density gradient centrifugation followed by HPLC purification.

Application Details

Application Notes: Anti-Apolipoprotein antibodies have been used for Indirect trapping ELISA for quantitationof antigen in serum using a standard curve, for Immunoprecipitation and for Westernblotting for highly sensitive qualitative analysis. Recommended dilutions: ELISA: 1/10,000-1/20,000. Western blot: 1/5,000-1/10,000. Immunoprecipitation: 1/100. Immunohistochemistry: 1/50-1/200.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0, 0.01 % Sodium Azide, None

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Dilute only prior to immediate use. Avoid cycles of freezing and thawing.

Storage: -20 °C

Storage Comment: Store vial at -20 °C prior to opening. Centrifuge product if not completely clear after standing at room temperature. For extended storage aliquot contents and freeze at -20 °C or below.

References for anti-APOA1 antibody (ABIN116540)

Bernthaler, Epping, Schmitz, Deplazes, Brehm: "Molecular characterization of EmABP, an apolipoprotein A-I binding protein secreted by the Echinococcus multilocularis metacestode." in: Infection and immunity, Vol. 77, Issue 12, pp. 5564-71, (2009) (PubMed).

Target Details for APOA1

Target: APOA1 (Apolipoprotein A-I (APOA1))

Alternative Name: Apolipoprotein A I (APO AI) (APOA1 Products)

Synonyms: Alp-1 antibody, Apoa-1 antibody, Brp-14 antibody, Ltw-1 antibody, Lvtw-1 antibody, Sep-1 antibody, Sep-2 antibody, Sep2 antibody, apoA-I antibody, apoa antibody, apoa1 antibody, cb49 antibody, wu:fb33f01 antibody, zgc:103718 antibody, MGC64335 antibody, MGC89745 antibody, Apo-AI antibody, ApoA-I antibody, APOA1 antibody, LOC100136573 antibody, apoa-i antibody, ApoAI antibody, apolipoprotein A1 antibody, apolipoprotein A-I antibody, apolipoprotein A-Ia antibody, apolipoprotein A-I S homeolog antibody, apolipoprotein A4 antibody, APOA1 antibody, Apoa1 antibody, apoa1a antibody, apoa1.S antibody, apoa1 antibody, LOC100136573 antibody, apoa-i antibody, apoa4 antibody

Background: Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids, an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.Synonyms: APOA1, Apo-AI, ApoA-I, ApoAI

Gene ID: 335

NCBI Accession: NP_000030

UniProt: P02647

Pathways: Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism